Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake

Ginkgo Bioworks Holdings, Inc.

Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.
In exchange, Ginkgo receives shares representing ~20% of Tower Biosecurity on a fully diluted basis.
Transaction expected to close in first half of 2026, subject to customary closing conditions.
Seller is Ginkgo Bioworks, Inc.; parent Ginkgo Bioworks Holdings is party for limited purposes.
No cash purchase price disclosed; consideration is solely an equity stake in the acquirer.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. entered into Stock Purchase Agreement with Tower Biosecurity, Inc. (effective 2026-02-26).

Action: entry
Agreement: asset purchase
Counterparty: Tower Biosecurity, Inc.
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Tower Biosecurity, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”).

View on SEC.gov

Browse all material agreements →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-012552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.